Provided By GlobeNewswire
Last update: Feb 4, 2025
SAN DIEGO, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX) today announced that it has completed an assessment of its business and operations, including the status of its program, resources, and capabilities. The Company has made the determination to discontinue all clinical studies evaluating TIDAL-01 and halt further development of the program. As a result, Turnstone’s management and its Board of Directors have initiated a process to explore and review strategic alternatives focused on maximizing shareholder value.
Read more at globenewswire.com0.36
0 (-0.8%)
Find more stocks in the Stock Screener
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.